References

Amin HM, Sopchak AM, Esposito BF, Henson LG et al (1995) Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Exp Ther 274: 34-9.

Bardolph EM, Taylor RH (1997) Sailors, scurvy, science and authority. J R Soc Med 90: 238.

Berry DA (1985) Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med 4: 521-6.

Berry DA (1995) Decision analysis and Bayesian methods in clinical trials. Cancer Treat Res 75: 125-54.

Chaput de Saintonge DM, Vere DW (1982) Measurement in clinical trials. Br J Clin Pharmacol 13: 775-83.

Ebbutt AF (1984) Three-period crossover designs for two treatments. Biometrics 40: 219-24.

Ellenberg SS (1989) Determining sample sizes for clinical trials. Oncology 3: 39-42.

Freedman LS, White SJ (1976) On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32: 691-4.

Freiman JA, Chalmers TC, Smith H, Kuebler RR (1978) The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N EngJ Med 299: 690-4.

Frey WG (1969) British naval intelligence and scurvy. N Eng J Med 281: 1430-33.

Gehan EA (1979) Clinical trials in cancer research. Environ Health Perspect 32: 31-48.

Kallis P, Tooze JA, Talbot S, Cowans D et al (1994) Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss: a prospective, randomized, placebo-controlled double-blind, clinical trial in 100 patients with chronic stable angina. Eur J Cardiothor Surg 8: 404-9.

Laska E, Meisner M, Kushner HB (1983) Optimal crossover designs in the presence of carryover effects. Biometrics 39: 1087-91.

Lind J (1753) A Treatise of the Scurvy. 460 Edinburgh.

Marsh BT (1990) Informed Consent. J R Soc Med 83: 603-6.

Pocock SJ (1992) When to stop a clinical trial. Br Med J 305: 235-40.

Pocock SJ, Geller NL (1986) Interim analyses in randomized clinical trials. Drug Information J 20: 263-9.

Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-15.

Spilker B (1991) Guide to Clinical Trials. Raven: New York; 1156 pp.

Strazis KP, Fox AW (1993) Malignant hyperthermia: review of published cases. Anesth Analg 77: 297-304.

Taves DR (1974) Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 15: 443-53.

Temple R (1997) Public hearings on Myotrophin: Peripheral and Central Nervous System Drugs Advisory Committee, May 8, 1997.

Thomas DP (1997) Sailors, scurvy and science. J R Soc Med 90: 50-4.

Treasure T, MacRae KD (1998) Minimisation: the platinum standard for trials? Br Med J 317: 362-3.

Whitehead J (1999) A unified theory for sequential clinical trials. Statist Med 18: 2271-86.

Willan AR, O'Brien BJ, Cook DJ (1997) Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trial 18: 121-30.

0 0

Post a comment